SBIR Phase II: Gene Signature Screening for Pancreatic Cancer Therapeutics from Sonoran Desert Extracts

SBIR 第二阶段：从索诺兰沙漠提取物中筛选胰腺癌治疗药物的基因特征

• 批准号: 1127476
• 负责人: Richard Kris
• 金额: $ 36.46万
• 依托单位: Nuvogen Research
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-12-15 至 2014-05-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1127476&HistoricalAwards=false
• 关键词: SBIR; Phase; II; Gene; Signature

This Small Business Innovation Research (SBIR) Phase II project is to address the high lethality of pancreatic cancer. Screening has begun with Phase IB funding, of natural products from the Sonoran Desert that have produced other promising drug candidates, testing effects on human pancreatic cancer cells. The objective of Phase II is to develop a drug candidate that alters expression of selected pancreatic cancer-related genes and that kills pancreatic cancer cells that express those genes. The drug candidates will be developed using a personalized medicine approach. The gene expression profiles (or genomics patterns) for many different pancreatic cancer tumors will be matched to the effects on genomics produced by the drug. This personalized approach could translate directly to clinical trials to pre-select patients most likely to respond to the drug. The broader impacts of this research are first to reduce deaths due to pancreatic cancer, which ranked fourth among the leading causes of cancer death with 35,240 deaths in the US in 2009. The 5-year survival rate for patients with metastatic disease is 1.8%. The societal impact and commercial value of targeting such a lethal disease are very high. Further, the personalized medicine approach to drug development will impact many oncology projects. The idea of matching each patient's genomics patterns with each drug that targets that pattern will be critical. Each kind of cancer is not one disease, but a wide spectrum of accumulated genomics changes that have to be addressed individually.

这个小企业创新研究 (SBIR) 第二阶段项目旨在解决胰腺癌的高致死率问题。 IB 期资助已经开始对来自索诺兰沙漠的天然产物进行筛选，这些天然产物已产生其他有前途的候选药物，并测试对人类胰腺癌细胞的效果。第二阶段的目标是开发一种候选药物，它可以改变选定的胰腺癌相关基因的表达，并杀死表达这些基因的胰腺癌细胞。候选药物将采用个性化医疗方法进行开发。许多不同胰腺癌肿瘤的基因表达谱（或基因组模式）将与药物对基因组的影响相匹配。这种个性化方法可以直接转化为临床试验，以预先选择最有可能对该药物产生反应的患者。这项研究更广泛的影响首先是减少胰腺癌造成的死亡，2009 年美国胰腺癌死亡人数为 35,240 人，在癌症死亡的主要原因中排名第四。转移性疾病患者的 5 年生存率为 1.8%。针对这种致命疾病的社会影响和商业价值非常高。此外，药物开发的个性化医疗方法将影响许多肿瘤学项目。将每个患者的基因组模式与针对该模式的每种药物相匹配的想法至关重要。每种癌症都不是一种疾病，而是一系列累积的基因组变化，必须单独解决。